Cisplatin Treatment Options in Ohio (Updated 8/25)

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NCT06029270

Recruiting

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the co... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/01/2025

Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio +1 locations

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8

Register for Updates

Learn More ›

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296

Recruiting

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma. Read Less

Gender:

ALL

Ages:

30 years and below

Trial Updated:

07/31/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular

Register for Updates

Learn More ›

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080

Not Yet Recruiting

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: Local Institution - 0087, Cleveland, Ohio

Conditions: Non-Small Cell Lung Cancer

Register for Updates

Learn More ›

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623

Recruiting

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. ABBV-400 and budigalimab are investigational drugs being developed for the... Read More

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. ABBV-400 and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of ABBV-400 in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 4 treatment groups. Two groups will receive budigalimab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive budigalimab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by budigalimab and pemetrexed. One group will receive the standard of care (SOC) pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 172 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with budigalimab or receive IV budigalimab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by budigalimab and pemetrexed, or IV SOC pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: The Mark H Zangmeister Center /ID# 272502, Columbus, Ohio

Conditions: Non Small Cell Lung Carcinoma

Register for Updates

Learn More ›

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

NCT01810913

Recruiting

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, wor... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +28 locations

Summa Health System - Akron Campus, Akron, Ohio

Cleveland Clinic Akron General, Akron, Ohio

UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

Summa Health Medina Medical Center, Medina, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

UHHS-Westlake Medical Center, Westlake, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

Register for Updates

Learn More ›

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

NCT04267848

Recruiting

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: Cleveland Clinic Akron General, Akron, Ohio +75 locations

Cleveland Clinic Akron General, Akron, Ohio

Aultman Alliance Community Hospital, Alliance, Ohio

Indu and Raj Soin Medical Center, Beavercreek, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Saint Elizabeth Boardman Hospital, Boardman, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Aultman Health Foundation, Canton, Ohio

Dayton Physicians LLC-Miami Valley South, Centerville, Ohio

Miami Valley Hospital South, Centerville, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Dayton Physician LLC - Englewood, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Columbus Oncology and Hematology Associates, Dublin, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Armes Family Cancer Center, Findlay, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Orion Cancer Care, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Dayton Physicians LLC-Atrium, Franklin, Ohio

Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio

Dayton Physicians LLC-Wayne, Greenville, Ohio

Wayne Hospital, Greenville, Ohio

Mount Carmel Grove City Hospital, Grove City, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Greater Dayton Cancer Center, Kettering, Ohio

First Dayton Cancer Care, Kettering, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

Memorial Hospital, Marysville, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

Springfield Regional Cancer Center, Springfield, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Dayton Physicians LLC - Troy, Troy, Ohio

Upper Valley Medical Center, Troy, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Saint Joseph Warren Hospital, Warren, Ohio

Saint Ann's Hospital, Westerville, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Saint Elizabeth Youngstown Hospital, Youngstown, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8

Register for Updates

Learn More ›

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667

Recruiting

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as p... Read More

Gender:

ALL

Ages:

Between 18 years and 79 years

Trial Updated:

07/31/2025

Locations: Indu and Raj Soin Medical Center, Beavercreek, Ohio +12 locations

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma

Register for Updates

Learn More ›

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767

Recruiting

This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Dayton Physicians LLC-Miami Valley South, Centerville, Ohio +14 locations

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma

Register for Updates

Learn More ›

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

NCT03811015

Suspended

This phase III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in diff... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +33 locations

Summa Health System - Akron Campus, Akron, Ohio

UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Premier Blood and Cancer Center, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

Summa Health Medina Medical Center, Medina, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

North Coast Cancer Care, Sandusky, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

Upper Valley Medical Center, Troy, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

UHHS-Westlake Medical Center, Westlake, Ohio

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Register for Updates

Learn More ›

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

NCT02375880

Completed

DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.

Gender:

ALL

Ages:

30 years and above

Trial Updated:

07/30/2025

Locations: University Hospitals, Case Medical Center, Cleveland, Ohio +1 locations

Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma

Register for Updates

Learn More ›

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738

Active Not Recruiting

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Cleveland Clinic Akron General, Akron, Ohio +113 locations

Cleveland Clinic Akron General, Akron, Ohio

Aultman Alliance Community Hospital, Alliance, Ohio

OhioHealth O'Bleness Hospital, Athens, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Indu and Raj Soin Medical Center, Beavercreek, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Saint Elizabeth Boardman Hospital, Boardman, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Aultman Health Foundation, Canton, Ohio

Dayton Physicians LLC-Miami Valley South, Centerville, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Premier Blood and Cancer Center, Dayton, Ohio

Dayton Physician LLC - Englewood, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton Veterans Affairs Medical Center, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Columbus Oncology and Hematology Associates, Dublin, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Armes Family Cancer Center, Findlay, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Orion Cancer Care, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Dayton Physicians LLC-Atrium, Franklin, Ohio

Dayton Physicians LLC-Wayne, Greenville, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

Wayne Hospital, Greenville, Ohio

Mount Carmel Grove City Hospital, Grove City, Ohio

Zangmeister Center Grove City, Grove City, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Greater Dayton Cancer Center, Kettering, Ohio

First Dayton Cancer Care, Kettering, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

Memorial Hospital, Marysville, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Dayton Physicians LLC-Signal Point, Middletown, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Mount Carmel New Albany Surgical Hospital, New Albany, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Saint Charles Hospital, Oregon, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio

OhioHealth Pickerington Methodist Hospital, Pickerington, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Dayton Physicians LLC-Wilson, Sidney, Ohio

Springfield Regional Cancer Center, Springfield, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Mercy Health Sylvania Radiation Oncology Center, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Dayton Physicians LLC - Troy, Troy, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Saint Joseph Warren Hospital, Warren, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

OhioHealth Westerville Medical Campus/Westerville Cancer Center, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

UHHS-Westlake Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Saint Elizabeth Youngstown Hospital, Youngstown, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Register for Updates

Learn More ›

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283

Active Not Recruiting

This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiat... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +76 locations

Summa Health System - Akron Campus, Akron, Ohio

Cleveland Clinic Akron General, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Indu and Raj Soin Medical Center, Beavercreek, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Saint Elizabeth Boardman Hospital, Boardman, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Dayton Physicians LLC-Miami Valley South, Centerville, Ohio

Miami Valley Hospital South, Centerville, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Premier Blood and Cancer Center, Dayton, Ohio

Dayton Physician LLC - Englewood, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Columbus Oncology and Hematology Associates, Dublin, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Armes Family Cancer Center, Findlay, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Orion Cancer Care, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Dayton Physicians LLC-Atrium, Franklin, Ohio

Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio

Dayton Physicians LLC-Wayne, Greenville, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

Wayne Hospital, Greenville, Ohio

Mount Carmel Grove City Hospital, Grove City, Ohio

Zangmeister Center Grove City, Grove City, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Greater Dayton Cancer Center, Kettering, Ohio

First Dayton Cancer Care, Kettering, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

Summa Health Medina Medical Center, Medina, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Mount Carmel New Albany Surgical Hospital, New Albany, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

Springfield Regional Cancer Center, Springfield, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Mercy Health Sylvania Radiation Oncology Center, Toledo, Ohio

Dayton Physicians LLC - Troy, Troy, Ohio

Upper Valley Medical Center, Troy, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Saint Joseph Warren Hospital, Warren, Ohio

Saint Ann's Hospital, Westerville, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Saint Elizabeth Youngstown Hospital, Youngstown, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma

Register for Updates

Learn More ›

Cisplatin Treatment Options in Ohio

Match to Clinical Trials

Browse by Cisplatin Treatment Options by City